Cancer, also called malignancy, is an abnormal growth of cells. There are more than 100 types of cancer, including breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. Symptoms vary depending on the type. Cancer treatment may include chemotherapy, radiation, and/or surgery. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. While these symptoms may indicate cancer, they can also have other cause.

The investigation of the malignancy gene helps in targeting the mutation directly in order to treat the disease or prevent it from growth. Advanced genomic testing is helpful in recognizing the DNA variations which can cause the gene alterations resulting in the formation of cancer cells. Genomic testing help oncologists to study the about individual genomic alterations that are unique for each individual, hence preparing personalized medicine to target such mutation cells will be forever helpful in treating the disease.

The growing studies and successful researches in the field have given rise to its market value and is proceeding on its way to grab the entire market and save it from the deadly cancer disease. The global cancer genomics size was valued to be $9216 million in 2014 and grew to be $17.8 billion in 2022. The rising investments by governments in biotech, growth in the number of genomics projects, decreasing sequencing cost and the increasing R&D activities for the development of novel therapies are serving as the main pillars for the growth of the oncogenomics market.